Overview Nevanac 3-Month Safety Study With QID Dosing Status: Completed Trial end date: 2006-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the safety of Nevanac 0.1% compared to Acular LS 0.4% and Vehicle in patients treated before cataract surgery and for approximately 90 days following surgery. Phase: Phase 3 Details Lead Sponsor: Alcon ResearchTreatments: KetorolacKetorolac TromethamineNepafenacOphthalmic SolutionsPharmaceutical Solutions